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ABSTRACT 
 
Clinical Pharmacokinetics and Safety of Zonisamide in Apparently Normal Dogs Following 
Single and Multiple Dosing. (August 2004)  
Jeremy Dane Perkins, B.S., Texas A&M University 
Co-Chairs of Advisory Committee:  Dr. Dawn Boothe 
                   Dr. Deborah Kochevar  
 
 
 
The purpose of this study was to design a dosing regimen and evaluate the safety of 
zonisamide (ZNS) following multiple dosing and to determine appropriate monitoring methods. 
Clinical pharmacokinetics were studied in 8 adult dogs (4 male and 4 female) ranging from 3 to 
4 years of age using a randomized crossover design following single intravenous (IV) and oral 
administration, 6.85 and 10.25 mg/kg, respectively. Samples were collected intermittently for 48 
hours. Dogs were then dosed orally (10.17 mg/kg) twice daily for 8 weeks. Blood samples were 
collected weekly and at discontinuation of the drug. Additionally, urine was collected to 
determine 24 hour urine ZNS clearance following IV administration. Safety was based on 
clinical pathology, thyroid and urine testing during both studies.  
 ZNS was measured using high performance liquid chromatography in serum, plasma, 
erythrocytes (RBC) and whole blood. Data were subjected to standard non-compartmental 
pharmacokinetic analysis using computer assisted linear regression (WinNonLin®). Comparisons 
were made in different compartments using one-way ANOVA to identify any differences. Safety 
parameters at study beginning and end were compared using a Student t-test.  
 ZNS concentrations differed among blood compartments after single dosing, with oral 
maximum concentration (Cmax) being greatest in RBC (28.73µg/ml) and least (14.36µg/ml) in 
plasma.  Volume of distribution also differed, being greater (1096.05ml/kg) in  plasma and least 
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in (379.23ml/kg) RBC. Clearance of ZNS was 57.55ml/hr/kg from plasma and 5.06ml/hr/kg 
from RBC. Elimination half- life in plasma was 16.4 hr in serum and 57.4 hr in RBC.  
Bioavailability was 126.8% for RBC and 189.6% for plasma.  
 Following multiple dosing, at steady-state, Cmax averaged 65.8µg/ml with fluctuations of 
17.2% between dosings. Accumulation of ZNS was 3.5 (plasma) and 4.3 (RBC).  Concentrations 
did not differ among blood compartments at the end of multiple dosing.  Although differences 
did occur across time in clinical pathology tests, all were within normal limits at study end 
except for T4.  
 In conclusion, ZNS dosed at 10 mg/kg twice daily for dogs would maintain therapeutic 
levels (10 to 70µg/ml) recommended in human epileptic patients. Therapeutic monitoring would 
be best measured in serum or plasma accompanied with thyroid and urine testing. 
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CHAPTER I 
INTRODUCTION 
Mechanism of Action 
Developed in Japan, zonisamide (ZNS), 3-sulfamoylmethyl- 1, 2 benzisoxazole, is a 
sulfonamide-based anticonvulsant.1 Dainippon Pharmaceutical Co. synthesized the drug in 1974. 
The Food and Drug Administration approved ZNS in 1998 for treatment of seizures related to 
human epilepsy. 1 The efficacy of ZNS is similar in the treatment of human epilepsy to 
phenobarbital and better than other classic drugs including valproic acid and phenytoin. 1 
Zonisamide appears to inhibit neuronal voltage-dependent sodium and T-type calcium channels.2 
Additionally, ZNS modulates the dopaminergic system 3 and accelerates the release of γ-amino 
butyric acid (GABA) from the hippocampus. 3,4 A potential advantage of ZNS is free radical 
scavenging which protects against the destructive nature of radicals, especially in neuronal 
membranes. 5 Finally, ZNS blocks the propagation of seizures from cortex to subcortical areas of 
the brain. 6 Although its mechanism of action is not certain, its antiepileptic efficacy, when 
combined with other anticonvulsants, supports an action that is similar to phenytoin 7 or valproic 
acid. 8 As such, an advantage to ZNS is that it is less likely to affect normal neuronal activity.7 
 
Clinical Pharmacology 
The clinical pharmacology of ZNS has been investigated in humans and laboratory 
animals( mice, rats and primates) with limited data reported in dogs.9-12 In humans, oral 
absorption is rapid and complete and is minimally impaired by food.1  Maximum concentrations 
occur between 2.8 to 3.9 hours. 1 Data regarding oral bioavailability is limited but was 84% in 
_______________ 
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humans in one report. 8 The volume of distribution (Vd) approximates 1.47 L/Kg, indicating 
distribution to total body water. 8 After 12 hours, the concentration of ZNS in the brain, liver, 
adrenal gland was twice that in plasma, suggesting good distribution to these organs.10 In 
addition, CNS penetration by transcapillary action across the blood brain barrier quickly 
equilibrates. 13 Rat studies indicate little efflux of ZNS from the brain, implying the drug is 
bound, or through other means, retained in the brain. 13 
Protein binding is 47.9 ± 0.9% in rats and between 40 and 60% in humans 14, suggesting 
that protein binding will not  limit the rapid movement into the brain. Further, when combined 
with other highly protein-bound drugs such as phenobarbital, unbound ZNS did not change .10  
The disposition of ZNS is complicated by binding to erythrocytes (RBC) as well as plasma 
proteins. As in the brain, ZNS concentration remains greater in RBC despite low serum 
concentrations11 In a study comparing mean whole blood and plasma or serum concentrations 
using area under the curve (AUC), RBC concentrations in whole blood were twice as high as 
plasma 15 and serum.11 This binding has been shown to have two components: saturable and non-
saturable. 13 Because of the large variation between serum and whole blood the saturable portion 
may reflect ZNS binding to carbonic anhydrase in epileptic patients.11 The accumulation of ZNS 
in RBC complicates calculation of volume of disposition (Vd). For example, Vd in humans 
declined apparently due to non-linear accumulation in RBC.7,8 The decrease in VD appears to 
lead to increased plasma drug concentrations.7 Accumulation in RBC, however, does not appear 
to impair distribution into the brain: approximately 50% of drug reaching the CNS in rats 
originated from RBC during a single transcapillary passage after determination concentrations in 
brain tissue. 13  The accumulation of drug in RBC is reversible, and the complex relationship 
between ZNS and RBC may make therapeutic drug monitoring of plasma or serum 
advantageous.8,16 
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Metabolism of ZNS includes both phase I and phase II hepatic metabolism with 
cytochrome P450 3A4 being the major isozyme17 and a glucuronidated compound the major 
metabolite.18 Renal elimination and recovery of ZNS indicates parent drug recovery of  35%.1 
Using radio labeled (carbon) ZNS administered to dogs, 83% of the drug was excreted in 72 
hour urine as the either the parent compound or metabolites. The remaining proportion was 
recovered in feces. 10   
The terminal half-life of ZNS in the dog following a single oral dose (20mg/kg) 
administration differed depending on the tissue studied with the shortest being 15 hours for 
plasma 10,12 and the longest, 42 hours for RBC. 10 The longer elimination half-life for plasma and 
RBC is beneficial because it allows a convenient dosing interval while minimizing dramatic 
fluctuations in ZNS concentrations that might cause recurrence of seizures. Twice daily dosing 
resulted in a 14% fluctuation of plasma drug concentrations in humans versus 27% with once 
daily dosing.8 Twice daily dosing is preferred in humans.19 Early studies suggesting that 
therapeutic concentrations for ZNS would be 10-70 µg/ml20 appear to have been confirmed with 
most recent studies indicating a therapeutic range  from 16.5 to 49.6µg/ml 9 when dosed twice 
daily. 
Non-linear pharmacokinetics have been reported in some human patients, particularly 
with chronic dosing, resulting in disproportionate, and thus unexpected, increases in drug 
concentrations compared to changes in dose. 7 Although the pharmacokinetics of ZNS 
apparently have not been reported in dogs, plasma concentrations, when receiving 75 mg/kg, 
never reached steady state over the course of thirteen weeks, while dosages of 10 to 30 mg/ kg 
attained steady state by week 13 and were proportionate to dose.12 The 75mg/kg dose 
concentrations were disproportionate to the concentrations of 10 and 30 mg/kg with the other 
dosages and may account for the non-linear pharmacokinetics seen in the previous article.  
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Safety 
In a toxicity study in the dog, doses of 10 to 30 mg/kg did not appear to cause serious 
side effects. 12 However, at 75 mg/kg dosed twice daily, hypoalbuminemia and slightly higher 
alkaline phosphatase activity indicated possible hepatic involvement. 12 Yet, the therapeutic 
index appears wide in dogs 7 with the lethal dose in dogs to be over 1000 mg/kg. 21 Chronic 
toxicity studies in dogs receiving up to 100 mg/kg for eight weeks revealed transient sporadic 
emesis and increased liver weight.21 In contrast, chronic dosing at 75 mg/kg once daily for 52 
weeks in beagles resulted in decreased appetite and weight loss, which resolved when the total 
daily dose was divided quarterly.  
Following approval of ZNS in humans, post-market studies have indicated rare adverse 
effects in selected organ systems. Renal tubular acidosis has been reported in the occasional 
patient, with resolution occurring once the drug is discontinued.22 Additionally, a series of cases 
of urolithiasis (calcium phosphate or calcium oxalate) has been described in children receiving 
ZNS for refractory epilepsy.23 This may reflect the carbonic anhydrase inhibitory activity of 
ZNS, by increasing calcium excretion with a subsequent decrease in urine citrate in the 
production of uroliths. 24  In another study, renal calculi occurred in 3% of human patients 
receiving the drug 7, although most uroliths were only a few millimeters in size.  As with renal 
tubular acidosis, uroliths and associated clinical signs resolved with discontinuation of ZNS 
therapy.25 In 3 out of 10 dogs treated with 75 mg/kg of ZNS, the urinary bladder was grossly 
affected and confirmed microscopically for damage; however, the author considered the changes 
to be insignificant in this study.12  
 Historically, sulfonamide-based drugs have been associated with reductions in 
circulating levels of thyroid hormones (T4 and T3) in dogs and humans.26 This reduction of the 
hormone is possibly due to the impairment of thyroglobulin iodination and coupling of tyrosines 
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in the thyroid tissue. 27,28 
 ZNS appears to be minimally involved in drug interactions which are typical of several 
other anticonvulsants (phenytoin, valproic acid) with high protein affinity. 10 Studies in vitro 
have demonstrated that ZNS binding to protein was unaffected by phenytoin and valproic acid 
concentrations.10 Interactions due ZNS concentration in RBC have caused anticonvulsant 
concentrations in serum to slightly increase. 29 ZNS does not appear to affect its own metabolism 
nor the metabolism of other drugs in animals or humans.30 However, the enzyme-inducing 
anticonvulsant phenobarbital, shortened the half-life from 27 to 36 hours in humans 14 and 
lowered plasma concentrations of the drug. 31  
 
Justification 
Antiepileptic failure can be life threatening. A common cause of therapeutic failure is a 
decline in antiepileptic drug concentrations below the minimum therapeutic range. The 
disposition of anticonvulsants can be complex, particularly with chronic dosing. Further, because 
antiepileptic drugs are given long term, the risk of adverse reactions and drug interactions 
increases. The most effective use of an antiepileptic is based on scientific studies that determine 
the proper dose and interval necessary to achieve and maintain concentrations throughout the 
dosing interval in plasma and central nervous system (CNS). The drug concentrations should be 
above the therapeutic minimum but below the therapeutic maximum. Although some studies of 
ZNS have been performed in dogs, these studies were largely implemented as part of the 
approval process for the drug in humans, thus are limited to toxicities and associated side effects. 
Currently, the amount of pharmacokinetic information available in the dog is insufficient to 
justify evidence-based administration of ZNS for patients suffering from idiopathic epilepsy. 
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Hypothesis 
 ZNS will safely achieve and maintain in canine plasma throughout the dosing interval 
concentrations considered therapeutic in humans when dosed orally at 10 mg/kg every 12 hours.  
 
Objectives  
1. To determine the oral dose and interval of ZNS necessary to maintain antiepileptic 
therapeutic concentrations, with minimal fluctuation during a dosing interval. Specific 
objectives are to: 
a. to determine the oral bioavailability; 
b. determine a dose necessary to achieve a Cmax within the therapeutic range 
described in humans; 
c. determine the maximum or a convenient oral dosing interval that will 
minimize fluctuation in drug concentrations throughout the interval;  
d. determine the major route of elimination in order to predict potential drug 
interactions or adverse reactions in unhealthy patients; 
e. based on a-c, recommend an oral dosing regimen;  
f. confirm the appropriateness of the oral dosing regimen when administered 
for several weeks; 
2. To determine the safety of ZNS when administered following multiple doses; Specific 
objectives are to: 
a. describe changes in clinical laboratory tests following multiple dosing that 
might be indicative of undesirable side effects; 
b. describe the effect of  multiple ZNS dosing on thyroid status; 
c. determine the effect of ZNS on urinary excretion of calcium and citrate; 
and 
3. To determine the most appropriate method of monitoring ZNS when used as an 
anticonvulsant. Specific objectives are to: 
a. compare the disposition of ZNS as measured in all blood compartments 
(plasma, serum, red blood cells and whole blood); and 
b. to determine the most appropriate (peak versus trough) sampling times. 
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 The combination of the data collected will provide information in the development and 
implementation of a dosing regimen to medicate dogs suffering from idiopathic epilepsy. 
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CHAPTER II 
 PREPARATORY STUDIES 
Introduction 
 The complex chemistry and kinetics of ZNS required several preliminary studies prior to 
implementation of the clinical pharmacokinetic studies. These included validation of the assay in 
multiple canine blood compartments (plasma, serum, whole blood and RBC) and urine. Further, 
because ZNS is not commercially available as a solution intended for IV use, and pure powder is 
not commercially available in amounts reasonably affordable, an IV preparation was prepared 
from oral tablets. Finally, the fraction of unbound ZNS was determined in canine plasma.  
 
Materials and Methods 
Chemicals and reagents 
A commercial preparation of zonisamide (Zonegran ®, Dainippon Pharmaceutical, 
Osaka, Japan) distributed by Elan Corporation (Dublin, Ireland) was used for the clinical 
pharmacokinetic and safety studies.  Sodium zonisamide was purchased from Sigma-Aldrich 
(St.Louis, Missouri) for use as a standard in analytical measurement of biologic fluids.  High 
performance liquid chromatographic (HPLC) analytical grade methanol and acetonitrile were 
purchased from E. Merck (Darmstadt, Germany). Citric acid monohydrate (E. Merck), potassium 
dihydrogen phosphate (E. Merck), and tetrabutylammonium hydrogen sulfate (Sigma –Aldrich), 
5- Sulfosalcyclic acid (Sigma- Aldich) were all of analytical grade. 
 
Analytical equipment 
The proper wavelength for detection of ZNS was determined by dissolving the sodium 
ZNS in methanol and subjecting it to dynamic spectrophotometric analysis using a Beckman DU 
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70 Spectrophotometer (Fullerton, California). The optimal signal was recorded at a wavelength 
of  245 nm.  
Reverse phase HPLC was used to quantify the concentration of ZNS in unknown 
samples. The HPLC system from Waters (Milford, Massachusetts) consisted of a pump (600 
controller), an autosampler (717 plus Autosampler) and an ultraviolet detector (Dual λ 
Absorbance detector). The ultraviolet detector was set at 245 nm with a sensitivity of 2.00AUFS 
an analytical column µ-Bondapak™ C18 (3.9 X 300mm, 125 A˚ 10 µm particle size) with a 
Sentry™ Guard column, 3.9x 20mm (µ Bondapak™ C18  ,125 A˚ 10 µm particle size). The 
mobile phase consisted of purified distilled water and methanol (70:30, v/v) filtered through a 47 
mm, 0.45 µm GH Polypro Hydrophilic Polypropylene Membrane filters from Pall Life Sciences 
(Ann Arbor, Michigan). The mobile phase was degassed with a Waters inline degasser. The flow 
rate was set to 1.4 ml/min.32 
 
Preparation of standards 
Canine blank plasma, whole blood, serum and urine were provided through the Texas 
A&M College of Veterinary Medicine Clinical Pharmacology Laboratory and represented 
pooled samples collected from apparently clinically normal dogs. Initial development of an assay 
to quantify concentrations of drug in whole blood, plasma, serum and urine was done in several 
steps. A stock solution of 100 µg/ml was prepared in methanol. The stock solution was diluted 
with methanol to obtain standard and control concentrations of 0.1, 0.3, 1, 3, 5, 10, 25, 30, 50, 
70, 75, and 100 µg/ml. A 60 µl of each standard and control was analyzed by HPLC using the 
equipment and mobile phase listed above. In methanol, the relationship between ZNS and the 
signal was characterized by an R2= 0.9999 with a linear regression equation of y = 33641x –
12716. The percent recovery of ZNS in plasma compared to the methanol stock was 88.6 %. The 
stock solution was stored at –20 ºC until needed for use in making standards and controls for 
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whole blood, serum, plasma, and urine. 
 
Biologic standards 
Blood and urine were collected via jugular venopuncture and urinary catheter, 
respectively. Whole blood was collected in lithium heparin Monoject® (Sherwood Medical, 
St.Louis, Missouri) tubes and clot tubes Monoject® (Sherwood Medical, St.Louis, Missouri). 
Standards and controls for whole blood were prepared from heparinized whole blood 
immediately after collection and prior to freezing to ensure that erythrocytes were not lysed in 
the process of freezing and thawing.33 Plasma was removed from heparinized whole blood 
following centrifugation (Beckman GPR Centrifuge, Fullerton, California) at 1600g for 15 
minutes. Plasma was harvested and stored frozen at –20 ºC until needed. Serum was removed 
from a whole blood in a clot tube and centrifuged at 1600g for 15 minutes. Serum was harvested 
and stored frozen at –20 ºC until needed. Urine was collected and pooled from three dogs and 
frozen at –20 ºC until needed. Standards and controls of whole blood, plasma, serum, and 
urine were made using the stock solution of sodium ZNS. A set of standards and controls were 
obtained in concentrations of 1 - 100 µg/ml. Whole blood controls were 1, 3, 7, 30, 45, 70, and 
90 (µg/ml). Plasma controls were 3, 7, 15, 20, 25, 45, 70, 75, and 90 (µg/ml). Serum controls 
were 2, 5, 7, 15, 18, 20, 25, 30, and 60 (µg/ml). Urine controls were 15, 45, 70, and 90 (µg/ml). 
The methanol from the pipetted standards and controls was evaporated using an N- Evap 
Analytical Evaporator® (South Berlin, Massachusetts) under a stream of nitrogen gas with vials 
containing standards immersed in a water bath maintained at 60 ºC. Once dry, 1 ml of fresh 
whole blood and thawed plasma, serum, and urine were added to their respective test tubes. All 
samples were lightly vortexed for 2 minutes, and then allowed to equilibrate throughout the 
sample at room temperature for 30 minutes before being frozen at –20 ºC until analyzed.  
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Serum, plasma and urine preparation  
 Standards and controls were allowed to thaw to room temperature before beginning the 
analytical preparation. Solid phase extraction with a Phenomenex® (Torrence, California) Strata 
C18-E (55 µm, 70 A°) cartridge was conditioned with 1 ml of methanol then 1 ml of purified 
distilled water.32 An aliquot of 200 µl of serum, plasma, or urine sample was added to the 
cartridge followed by a 700 µl wash of purified distilled water. The sample was eluted from the 
cartridge under vacuum with 200 µl of methanol. A 60 µl sample of the elute was injected into 
the HPLC sample using the same equipment and method mentioned above.  
 
Whole blood preparation 
Whole blood samples, standards and controls were allowed to reach room temperature 
before analysis. Each then was vortexed for 30 seconds to homogenize the blood. A 300 µl 
aliquot of whole blood and 600 µl of an acetonitrile: methanol mixture (90:10)34 was vortexed 
for 30 seconds then centrifuged using Beckman GPR Centrifuge (Fullerton, California) at 3000 
RPM for 10 minutes at 5 °C. The supernatant was then added to a Phenomenex® (Torrence, 
California) Strata C18-E (55 µm, 70 A°) cartridge which had been preconditioned with 2 mls of 
methanol. The sample was eluted with 1 ml of methanol into individual test tubes. The elute was 
evaporated using a N- Evap Analytical Evaporator (South Berlin, Massachusetts) under a stream 
of nitrogen gas with a water bath set to 60 º C until dry. The residue was then dissolved with 200 
µl of methanol. A 60-µl injection of the sample was injected into the HPLC machine for 
analysis.  
 
RBC concentration 
 The RBC concentrations were determined mathematical using plasma and whole blood 
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concentrations and each dog’s hematocrit.  The RBC equation is: 
RBC= [ ( ) ]PB C1CH
1 H−−   
RBC = concentration in packed red blood cells,  H= fractional hematocrit, CB = whole blood 
concentration of ZNS, and CP= plasma concentration of ZNS (see Appendix B). 
 
Intravenous solution 
Ten capsules of Zonegran® (ZNS) 100mg were emptied into a beaker. Methanol (30 ml) 
was added to the beaker and stirred vigorously with a stir bar for 10 minutes. The supernatant 
was removed and filtered through a Pall Gelman Laboratory (Ann Arbor, Michigan) 13mm GHP 
Acrodisc® 0.45µm syringe filter. The supernatant was then evaporated to dryness under a stream 
of nitrogen. Once dry, methanol was added to the residue and vortexed for 10 minutes and then 
allowed to rest for 20 minutes.  The supernatant was removed and filtered with a 0.45µm syringe 
filter. The filtrate was dried under a stream of nitrogen. The residue was removed from the 
holder and weighed. The residue was treated as pure ZNS.  
To assure all drug was dissolved (thus avoiding IV injection of particular matter), 
several solvents were investigated for their potential safe use. These included dimethyl sulfoxide 
(DMSO), ethanol and saline.  After adding an equal amount of ZNS to three test tubes, 20 mls of 
DMSO, ethanol, and saline were added. The tubes were vortexed for 2 minutes and then allowed 
to rest for 30 minutes at room temperature. The solubility of zonisamide in ethanol and DMSO 
were seen to be acceptable based on absence of visible precipitates. Impact of each of these 
solvents on RBC integrity was then considered in order to avoid solvent-induced release of ZNS 
that had accumulated in RBC. Because DMSO causes RBC hemolysis when administered as 
more than a 10% solution, 35 ethanol was considered to be the more likely candidate.36 Despite 
its clinical use for treatment of ethylene glycol toxicity (20 % ethanol) in dogs (5.5 ml/kg every 4 
         13
hours or 1.1 gm/kg every 4 hours)37, ethanol is associated with adverse events and is 
characterized by a LD100 of  5.365 g/kg.38 Based on the ethylene glycol dose, no more than 4 
g/kg of ethanol was determined to be safe for the test subjects involved (see Appendix A).  
A targeted solution of 8 mg/ml of ZNS in ethanol was prepared as follows. The 
measured amount ZNS was dissolved with 33% ethanol 9 until no visible drug was present. 
Saline was then added at a ratio of 2:1 (saline: ethanol) to dilute the effects of ethanol and to 
lessen hemolysis. The ZNS solution was filtered through a Whatman® (Clifton, New Jersey) 
25mm 0.2µm PES syringe filter. Afterwards, the solution was stored at 5º C until analysis or 
administration. 
To confirm both the concentration of drug and purity of the drug, standards and controls 
were made using the commercially available ZNS dissolved in the ethanol (1): saline (2) solution 
used for the IV preparation. A set of standards and controls were made from 1- 150 ug/ml. 
Controls were 3, 15, 45, 85, and 125 (µg/ml). Several aliquots of the intravenous solution were 
added to verify the concentration of the intravenous solution in duplicate. Based the on the 
regression line equation for the sum of least squares (y = 91546x –96640, R2= 0.9985) for the 
standards, the IV solution concentration was extrapolated to 3.9 mg/ml, which was confirmed 
following formulation of a second intravenous solution with a concentration of 4.0 mg/ml.  
 
Total protein binding 
Total protein binding in canine plasma was based on equilibrium dialysis 39,40 using  a 96 
well-plate dialyzer (Harvard Apparatus, Holliston, Ma) with molecular cutoff of 5000 Daltons. 
To determine the percentage of unbound drug, six concentrations within the therapeutic range 9 
were chosen to be evaluated. Aliquots of the stock solution ranging from 10– 50 µg /ml were 
dried under a stream of nitrogen. Phosphate buffered saline (PBS), 0.1M, was added to the 
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residue until dissolution. Standards and controls were made in the same manner as above. Frozen 
plasma was removed and thawed at room temperature.  
A 200 µl aliquot of PBS- ZNS solutions was added to one side of the 96- well-plate and 
capped. A 200 µl aliquot of drug-free plasma was added to the other side and capped. The plate 
was then allowed to equilibrate for 24 hours at 37 °C. After 24 hours the samples were removed 
and prepared for analysis by HPLC. The preparation and equipment were the same techniques 
used for serum, plasma, and urine previously discussed. 
 
Results 
Validation of analytical assay 
 Analysis of ZNS  in whole blood, plasma, and serum were validated using HPLC. 
Standard and control concentrations were compared to known concentrations using an equation 
derived from the sum of least squares. Controls and the accompanying standard curve were 
considered acceptable if the percentage error (difference between actual and predicted divided by 
the actual) was less than + 15%. Intra- assay and inter-assay variability were determined. 
 Intra-assay accuracy for serum controls predicted within 95.5 ± 4.8% (range 91.3 – 
106.0%) with a regression equation y = 44114x + 19636. Plasma was 97.7 ± 6.0% (range 88.0-
111.0%) with a regression equation of y= 43175x +8707.9. Whole blood was 91.4 ± 6.8% (range 
83.4 - 100.7%) with a  regression equation y= 64586x – 16687 . 
 Inter-assay controls precision for serum was 99.5 ± 3.7% (range 94.5 – 105.8 %). 
Plasma was 99.5 ± 5.6 % (range 92.2 – 109.8). Whole blood precision was 95.2 ± 6.4 % (range 
84.2 – 101.5%). Urine results was 103.2 ± 8.86% (range 95.05- 113.05%) with a regression 
equation y=81270x – 630244, refer to appendix C for all data. The retention time of ZNS was 
7.8 minutes regardless of the body fluid (Fig 1). 
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Fig 1. Serum, plasma, whole blood, and urine chromatographs. Each chart represents an example of four different 
samples (A=serum ZNS, B= plasma, C= whole blood, D= urine) tested through HPLC analysis. The retention time is 
7.8 minutes for the ZNS samples. 
 
 
 
Protein binding 
 Using an established therapeutic window for humans, the percentage of unbound versus 
bound zonisamide was determined. With concentrations ranging from 6 to 55 µg/ml, the average 
unbound portion of zonisamide available for pharmacological activity was 60.48 ± 13.47% 
(Table 1).  
 
Intravenous preparation results 
Both of the tested IV solutions were compared against what was weighed and calculated 
and were found to be 15% different than what was initially calculated. The final concentrations 
of the prepared solution were, 3.9 and 4.0 mg/ml. 
B
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Table 1. Protein binding of ZNS. a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
  
  aProtein binding for the therapeutic window of 6-55 µg/ml concentration in the 
   body. Bound and unbound percentages are listed for individual concentrations. 
 
 
 
Discussion 
Validation of assay  
 Establishing assays for the prediction of concentrations in plasma, serum, urine, and 
whole blood are important for the modeling of the disposition of ZNS in the dog. All the tested 
assays were capable of controls predicting within ± 15% of the expected concentration. The 
percentage difference was acceptable and was used in determining the ZNS concentrations for 
the appropriate blood compartment.  
 
Protein binding  
 Binding of ZNS to plasma proteins was determined to estimate the amount of drug that 
would be free for pharmacological activity as well as to predict any potential drug interactions at 
the level of protein binding. 39,41 Studies revealed the unbound fraction of drug to be 60.48 ± 
Therapeutic window 
concentration (µg/ml) 
Unbound Drug 
% 
Protein Bound Drug 
% 
6 58.811 41.189 
10 76.093 23.907 
15 43.466 56.534 
25 55.515 44.485 
35 73.104 26.896 
40 47.886 52.114 
50 77.808 22.192 
55 51.164 48.836 
   
Average 60.481 39.519 
Standard Deviation 13.447 13.447 
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13.4%. The percentage of the drug bound is close to the percentage bound by rats.  In rat studies, 
protein binding was found to be 47.9 ± 0.9%.10 The proportion of protein binding was not 
deemed sufficient to contribute to drug interactions, but the apparent volume of distribution and 
clearance could be lowered because of the proportion bound hindering movement from 
circulation to specific active sites.  
 
Intravenous preparation 
In developing the intravenous solution, care was taken to ensure safety for the dogs. 
Filtering of the finished preparation was performed to ensure that any microscopic particulate 
was eliminated from the solution. However, this does not guarantee removal of pyrogens. 
Analysis of the final finished solution indicated that the final concentration of 4 mg/ml was 
lower than that anticipated based on preparation (8 mg/ml). Reasons for the differences might 
include a calculation error (less likely as FDA approved capsules were used as measured units 
and duplication of the procedure yielded strikingly similar concentrations).  It also is possible 
that apparent soluble components in the oral form were soluble in methanol and were 
incorporated in to the final weight of the powder used in the preparation of the IV solution. 
Because purity was not established, this is possible, but the magnitude of contamination was 
sufficiently large that HPLC analysis should have indicated some type of competing material. 
However, no peaks other than ZNS were evident. The most likely explanation of lower than 
expected concentrations of ZNS following extraction from oral capsules was decreased recovery 
(50%) due to binding of  active to inactive ingredients. However, less than ideal recovery was 
not a detractor to the success of the study; the IV dose was based on a concentration of 4 mg/ml 
of ZNS in ethanol. At this dose, each animal would also receive 5 mg/kg of ethanol as a 33 % 
solution.   
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CHAPTER III 
SINGLE DOSE PHARMACOKINETIC DATA 
Introduction 
 Single dose evaluations are used to characterize pharmacokinetic data to develop a 
dosing regiment for long-term therapy. Data collected was used to calculate absolute 
bioavailability for ZNS to determine the extent of absorption following oral administration. 
Further, the single dose study provided a basis for a dosing regimen (dose and interval)  when 
ZNS is used as an antiepileptic drug.  The design of the study allowed for non-biased and 
independent evaluation of data collected 
 
Materials and Methods 
Research subjects  
 All research protocols were approved by the Texas A&M University Lab Animal Care 
Committee. Eight (4 male and 4  female ) hound dogs (29.41 ± 5.36 kg) ranging from 3 to 4 
years of age were studied using a randomized cross-over design. Dogs were apparently healthy 
based on physical examination, baseline blood chemistry, complete blood count, thyroid testing 
and urinalysis. 
 
Data collection 
Dogs were studied in IV (6 mg/kg) and oral (10 mg/kg) pairs. 20 For at least six weeks 
prior to the study, dogs were acclimated to their environment and diet. Immediately prior to the 
study, random urine samples were collected in all animals for baseline urine citrate concentration 
and calcium:creatinine ratio. Immediately prior to each study, indwelling external jugular 
catheters were aseptically placed using manual restraint. Following administration of ZNS, 
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whole blood samples were collected in lithium heparin Monoject® (Sherwood Medical, 
St.Louis, Missouri) tubes intermittently for at least three plasma elimination half-lives as 
determined in a pilot study of two dogs. For the IV study, samples were collected at 0 (before 
dosing) and at 2.5, 5, 10, 15,  20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360, 720, 840, 
1200, 1440, 1800, and 2160 minutes. Administration of the intravenous solution through a 
cephalic vein was performed over 10 minutes to ensure the health and safety of the patient. A 
veterinarian assisted with the monitoring of heart rate, pulse pressure through palpation of 
femoral pulse, and the mentation of the subjects for any adverse effects from the ethanol. 
Following a one-week washout, ZNS was administered via the alternative route. For the oral 
study, sample collection occurred at 0 (before dosing) and at 15, 45, 60, 75, 90, 120, 150, 180, 
240, 300, 360, 720, 840, 1200, 1440, 1800, 2160, and 2880 minutes. Urine was collected during 
IV administration for the first 24 hours to determine the percent and rate of elimination parent 
ZNS through the renal system via urinary catheter.  
  
Data analysis 
Concentrations were quantitated in serum, plasma, whole blood, and urine; refer to 
chapter II.  Drug concentration versus time data for each animal was subjected to standard non-
compartmental pharmacokinetic analysis using computer assisted linear regression software 
WinNonLin® (Pharsight Corporation, Mountain View, California). Area Under the Curve 
(AUC) was determined to infinity using the linear trapezoidal method; AUC was subsequently 
used to calculate model independent parameters including mean residence time (MRT) and 
absolute bioavailability.  The extent of absorption was based on absolute bioavailability, F, of 
the oral product and calculated for each animal from the equation:   
F = (AUCoral * DoseIV)/ (AUC IV * Dose oral). 
         20
Rate and extent of absorption was based on estimated peak concentration (Cmax) and time to peak 
(Tmax). Duration of exposure to ZNS was based on mean residence time (MRT), and elimination 
half-life (t1/2). From the IV data, Vd, t1/2 and clearance (CL) was calculated.  All parameters, 
including RBC accumulation (plasma to whole blood drug concentration), were reported as 
mean + standard deviation. The exception, half-life, was reported as harmonic mean and pseudo-
standard deviation. One Way Analysis of Variance (ANOVA) was used to determine if 
significant differences occurred between each blood compartment. Tukey’s (HSD) was used to 
determine which compartment parameters differ. 
 
Results 
Oral administration 
 Utilizing noncompartmental analysis concentrations of ZNS defined dispositional 
differences among the tested blood compartments (Fig 2). The AUC (0-∞) for RBC (3011.98 ±  
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 Fig 2. Single oral dose concentrations of ZNS. Data after single oral dose of ZNS (µ= 10.25 mg/kg) plotted 
logarithmic with calculated concentrations on the y-axis and minutes on the x-axis.  
         21
1732.99 hr*µg/ml) was greater (p=0.0001) than serum (354.47 ± 86.02 hr*µg/ml), plasma 
346.52 ± 80.24 hr*µg/ml) and whole blood (1107.43 ± 315.37 hr*µg/ml ). The CMAX in serum 
and plasma of 13.17 ± 1.99 µg/ml and 14.36 ± 2.29 µg/ml, respectively, were less than CMAX in 
RBC (28.74 ± 4.37 µg/ml, p=0.0000). The concentrations of ZNS in systemic circulation 
reached TMAX in 2.5 ± 0.65 hr (serum), 2.75 ±1.25 hr, 3.5 ±1.04 hr(whole blood) and 4.25 ±1.33 
hr (RBC). RBC time to TMAX was greater (p=0.0348) than other blood compartments. The time 
from administration to absorption of ZNS, Tlag, was 0.48 ± 0.3 hr (serum), 0.21 ±0.29 hr 
(plasma) 0.04 ± 0.01 hr (whole blood) and 0.04 ± 0.01 hr (RBC) (Table 2). 
 
 
Table 2. Pharmacokinetic data of ZNS following oral administration. a 
  
Serum 
(n=8) 
Plasma 
(n=6) 
Whole Blood 
(n=6) 
RBC 
(n=6) 
p-value 
 
AUCINF(observed) 354.47A ±86.02 346.52A ±80.24 1107.43A  ±315.37 3011.98B ±1733  0.0001 
(hr*ug/mL)           
Cmax  13.17 A ± 1.99 14.36 A ± 2.29 19.08 A,B ±2.29 28.74 B ±4.37 0.0000 
(µg/ml)           
MRT  26.82A ±6.56 26.89A ±4.6 66.6A,B ±23.6 131.56B ±98.9 0.0061 
(hr)           
t1/2 17.37A ±4.9 17.2A ±3.59 45.80A,B ±17.82 90.99B ±70.07 0.0068 
(hr)           
Tmax 2.5A ±0.65 2.75A,B ±1.25 3.5A,B ±1.04 4.25B ±1.33 0.0348 
(hr)           
V_F 729.11A ±151.9 764.75A ±150 595.49B ±179.48 0.40C ±0.11 0.0000 
(ml/kg)           
CL_F 30.50A ±8.48 31.70A ±7.28 9.55B ±2.83 0.01C ±0 0.0000 
(ml/hr/kg)           
Tlag 048 ±0.3 0.21 ±0.29 0.04 ±0.1 0.04 ±0.01   
(hr)           
F 163.61 189.63 108.16 126.80   
 
a Letters (A,B,C) within each parameter denote different compartments (α=0.05, significant when p< 0.05) with 
Tukey’s HSD. Parameters AUCINF= Area under the curve measured to infinity observed, Cmax= the maximum 
concentration, MRT= Mean residue time, t ½= elimination half life, Tmax= time of maximum concentration, V_F= 
Volume of distribution, Cl_F= Clearance rate, Tlag= Time between administration and absorption, F= absolute 
bioavailability. See appendix B for equations.  
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RBC compartment had a greater (p=0.0061) MRT (31.56 ± 98.9 hr) than serum (26.82 ± 6.56 hr) 
and plasma (26.89 ±4.60 hr). Serum, plasma, and whole blood took 17.37 ±4.9 hr, 17.2 ±3.59 hr, 
and 45.8 ±17.82 hr, respectively, to eliminate which was less (p= 0.0000) than RBC 
compartment 90.9 hr ± 70.7 hr. With a single dosage of 6.85 mg/kg IV and 10.25 mg/kg oral, 
bioavailability was determined to be 163.61 % (serum), 189.63 %, (plasma), 108.16 % (whole 
blood) and 126.80 % (RBC).  
 
Intravenous administration 
Effects presumed to be  related to large infusion of ethanol, salivation and ataxia, were 
not serious and quickly dissipated within 25 minutes of administration.42 No other side effects 
were noted. 
 Concentrations of ZNS were greater in RBC than the other compartments (Fig 3).  
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Fig 3. Single dose intravenous concentrations of ZNS. Data after single intravenous dose of ZNS 
(µ= 6.85 mg/kg) plotted logarithmic with calculated concentrations on the y-axis and minutes on 
the x-axis.  
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Maximum concentrations after distribution differed for serum (8.42 ± 2.71 µg/ml), plasma (6.83 
±1.07 µg/ml), whole blood (12.58 ± 1.15 µg/ml) and RBC (22.54 ± 3.98 µg/ml). The AUC (0-∞)  
for RBC (1587.44 ± 630.38 hr*µg/ml) and whole blood (684.23 ± 256.84 hr*µg/ml ) were  
greater   (p=0.000) than serum (144.8 ± 53.84 hr*µg/ml) and plasma (122.12 ± 32.54 hr*µg/ml ). 
The observed Vd of serum (1193.05 ± 509.56 ml/kg) and plasma (1096.05 ± 251.64 mg/ml) 
were greater (p= 0.0000) than whole blood (673.14 ± 61.49 ml/kg) and RBC (379.23 ± 43.20 
ml/kg) (Table 3).  
 
Table 3. Pharmacokinetic data of ZNS following IV administration. a 
 
Serum 
(n=8) 
Plasma 
(n=6) 
Whole Blood 
(n=6) 
RBC 
(n=6) 
p-value 
 
AUCINF(observed) 144.80A 122.12A 684.23B 1587.44B 0.0000 
(hr*ug/mL) ±53.84 ±32.54 ±256.84 ±630.38   
Cl(observed) 54.62A 57.55A 11.38B 5.06B 0.0000 
(mL/hr/kg) ±23.29 ±11.41 ±2.93 ±1.83   
Cmax (observed) 8.42 A 6.83 A 12.58 B 22.54 C 0.0000 
(µg/ml) ± 2.71 ± 1.07 ± 1.15 ± 3.98   
MRTINF(observed) 22.43A 19.47A 63.33B 83.8B 0.0000 
(hr) ±7.76 ±4.87 ±19.6 ±30.47   
t1/2 16.37A 12.9A 44.22B 57.41B 0.0000 
(hr) ±7.83 ±3.58 ±13.78 ±21.69   
Tmax 0.93 0.44 0.49 0.63 0.8614 
(hr) ±1.00 ±0.54 ±0.76 ±0.81   
Vd(observed) 1193.05 A 1096.05 A 673.14 B 379.23 B 0.0000 
(mL/kg) ± 509.56 ± 251.64 ± 61.49 ± 43.2   
 
a Letters (A,B,C) within each parameter denote different compartments (α=0.05, significant when p< 0.05) with 
Tukey’s HSD. Parameters AUCINF= observed Area under the curve measured to infinity, Cl= observed clearance 
rate, Cmax= the maximum concentration, MRTINF= Mean residue time measured to infinity, t ½= elimination half 
life, Tmax= time of maximum concentration, and Vd= Volume of distribution. See appendix B for equations. 
  
 
Elimination half-life of ZNS was less (p=0.0000) in serum (16.37 ± 7.83 hr) and plasma (12.90 ± 
3.58 hr) versus whole blood (44.22 ± 13.78 hr) and RBC (57.41 ± 21.69 hr). MRT in serum 
(22.43 ± 7.76 hr) and plasma (19.47 ± 4.87 hr) were less (p=0.0000) than whole blood (63.33 
±19.6 hr) and RBC (83.80 ± 30.47 hr). Clearance of ZNS in serum (54.62 ± 23.29 ml/hr/kg) and 
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plasma (57.55 ± 11.41 ml/hr/kg) were greater (p=0.0000) than whole blood (11.38 ± 2.93 
ml/hr/kg) and RBC (5.06 ± 1.83 ml/hr/kg).  
 
Urine ZNS elimination 
  The  percent recovery of ZNS from urine in the first 24 hours was 5.0 ± 0.34 % . Renal 
clearance was  of 8.73 ± 0.6 µg/ml (0.0087 ± 0.0 mg/ml). (Table 4).  
 
          Table 4. Urine ZNS recovery and elimination rate.a 
 
 
 
 
 
 
 
             aThe percent (%) recovery and renal clearance following single IV dosing in 3 apparently 
          healthy hound dogs receiving zonisamide (6.85 mg/kg) IV 
 
 
Discussion 
 Single dose administration was used to establish a model for development of long-term 
therapy through the establishment of the disposition of ZNS. Studies done previously were 
performed for purposes of human implementation; however, limited data for the dogs does exist. 
In comparing the canine results among  investigators, , elimination half-lives were similar. 
Plasma and RBC times previously reported were 14 and 42 hours, respectively, following a 20 
mg/kg dose of ZNS10  compared to 16.9 (plasma) and 58.01 (RBC) hours in this study. 
Elimination half-life of ZNS is  greater in humans, ranging among investigators between 52 and 
60 hrs8,14 in plasma. AUC in plasma was observed at 486 hr*µg/ml 10 comparing to 346.52 
 Mean Std. Dev 
% Recovered of ZNS drug in Urine 5.00 ± 0.34 
Renal clearance rate                    
(mg/ min) 0.009 ± 0.00 
Renal clearance rate 
(µg/ min) 8.73 ± 0.60 
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hr*µg/ml in this study. The Vd was 0.72 L/kg in plasma compared to 0.9 L/kg for dogs reported 
in data released from the manufacturer’s laboratory.10 Compared to humans (1.27 L/kg)14 
receiving ZNS , Vd in dogs was less. The amount of time to reach maximum plasma 
concentrations in humans (4-6 hrs) 14 was greater than observed in this study (2.75 hrs).  
 The concentration of ZNS differed among the blood compartments following oral 
administration. Data reflected Cmax  in RBC greater than other compartments. The AUC (o-∞) and 
elimination half-life were greater for RBC corresponding to a MRT 131.56 hours. RBC values 
were different from data collected in serum and plasma. The calculated parameters for serum and 
plasma showed no differences statistically in the data observed between the compartments. 
Whole blood differed from all compartments in the apparent Vd observed (595.49 ml/kg) and Cl 
(9.55 ml/hr/kg). Determination of bioavailability in noncompartmental analysis revealed values 
ranging from 108.16-189.63 % were greater than the expected human values (84%).8 Intravenous 
observations noted similar differences between RBC and serum as in oral administration. Values 
seem consistent with RBC having greater concentration and elimination rates that are longer than 
other compartments.  
 The apparent reason for RBC differences is due to binding of ZNS to RBC. 11 The 
pharmacologic activity of ZNS is extended as seen in elimination half-life because of the uptake 
and confinement of ZNS.11 The noted differences observed in concentrations across the same 
time point can be due to the analysis of serum and plasma versus whole blood. With the absence 
of RBC in serum and plasma, the concentrations at those time points are lower. Analysis of the 
data revealed elevated bioavailability that need to be explained. The equation for bioavailability 
(appendix B) uses the data collected from AUC (0-∞) from IV and oral administration. Possible 
reasons for the increased value were explored in the calculation of AUC (0-∞) .The kinetic 
software calculates Cl using Dose/ AUC(0-∞).Considering that AUC (0-∞)  and Cl are inversely 
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proportionally, changes to one affect the other inversely. The use of ethanol as a vehicle for IV 
administration may have contributed to bioavailability that exceeded 100%. Ethanol can increase 
renal blood flow and urine output 43,44 and, presumably, the elimination of ZNS. Ethanol causes 
hepatic saturation of microsomal enzymes leading to longer exposure of ethanol when large 
doses of ethanol are administrated.43 Ethanol also is reported to induce cytochrome P450 
isozyme 3A4 (CYP 3A4)45  the microsomal enzyme responsible for metabolism in humans.17 
Due to ethanol saturation of microsomal enzymes and the induction of CYP 3A4 and  extensive 
renal elimination of ZNS a possible reason for the to the high bioavailability is due to the effects 
of ethanol on increasing clearance which inversely lowers the AUC (0-∞)  by decreasing  ZNS 
concentrations in vivo. However, the extent of such evidence is hypothesized, due to the unlikely 
event that induction of the CYP3A4 could occur quickly based on the single injection of ethanol 
and the time it would take in vivo to cause induction. 
 In developing a regimen  for multiple dosing, the steady state concentrations in the dogs 
would be attained between 4 to 7 days for plasma and whole blood, respectively. These 
estimations are based on 97 - 99 % of steady state concentrations being reached in 5.5 half-
lives.46 With an anticipated fluctuation of 14% following twice daily dosing 8, a dose of 10 
mg/kg (~300 mg ) was used to achieve therapeutic levels suspected in humans ranging from 16.5 
to 49.6µg/ml. 9 The length of time estimated to maintain therapeutic levels was considered 
acceptable due to the relatively small fluctuation ensuring that concentrations did not fall below 
what was considered to be the window. The accumulation of ZNS within the dog was 
determined to be 2.02 in plasma and 4.09 in whole blood data collected if administered twice 
daily. Anticipation of higher concentrations because of the accumulation index provides 
additional support to the maintenance of therapeutic levels which was observed in multiple 
dosings.  
         27
 In conclusion, ZNS appears to be eliminated by means other than renal excretion of the 
parent compound. Based on the results of this study, a dose of  10 mg/kg is recommended every 
12 hrs in order to achieve and maintain effective concentrations. Because tissue concentrations 
significantly differed following single dosing,  monitoring methods might best be determined 
following multiple dosing.  
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CHAPTER IV  
MULTIPLE DOSE PHARMACOKINETIC DATA 
Introduction 
 Multiple dose studies were performed to verify that the dosing regimen derived from the 
single dose study would maintain therapeutics concentrations and monitor the fluctuation 
between twice daily dosings. The data collected assisted in the development of a long-term 
regiment by recommending dosages and frequency of dosing. Safety was evaluated based on 
clinical pathology and thyroid testing with a focus on organs of excretion.  
 
Materials and Methods 
Data collection 
Eight apparently healthy dogs (used in single-dose studies) were studied. Zonisamide 
was administered orally every 12 hours at 10 mg/kg. Blood samples and urine were collected 
prior to dosing to determine baseline for clinical laboratory tests, urine and thyroid hormone 
analysis. Peak and trough blood samples were collected (based on the single-dose study) and 
once a week for eight weeks beginning with the first dose. Clean catch urine samples were 
collected at each trough sampling time. After the final dose of ZNS at the end of the eight weeks, 
blood was collected at 0 (time of last dose) and 1.5, 3, 16, 28, 48, 72 hours. At the end of the 
dosing period, clinical laboratory tests, determined through automated assays validated in the 
dog, urine and thyroid hormone analysis were repeated. Thyroxin-4 (T4), free and total were 
analyzed through equilibrium dialysis and thyroid-stimulating hormone (TSH) was evaluated 
through automated chemiluminescence. Citrate levels were measured through ion 
chromatography.  
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Data analysis 
  Samples were analyzed using methods described in chapter II. From the chronic dosing 
data, non-compartmental analysis was used to determine AUC(0- ∞) ,  percent fluctuation, 
accumulation, and elimination half-life. Peak drug concentration (Cmax) and minimum 
concentrations was evaluated and accumulation was determined. One-way ANOVA was used to 
determine if any differences occurred between the blood compartments (serum, plasma, whole 
blood, and RBC) and to assist with determining disposition and therapeutic monitoring. Tukey’s 
(HSD) was used to determine which compartment parameters differ.  
Clinical laboratory tests and urinary calcium: creatinine ratios and urine citrate 
concentrations were compared to a baseline at the study’s end using a paired Student’s t test. 
Level of significance for all values was if p-value is less than α=0.05. 
 
Results 
 Concentrations of ZNS appeared to attain steady state by day 7 in all analyzed blood 
compartments (Fig 4). Maximum concentrations of ZNS following administration averaged 
52.45 ug/ml (serum), 56.01 µg/ml (plasma), 55.56 µg/ml (whole blood), and 55.19 µg/ml (RBC) 
among tested dogs (Table 5). The percent fluctuation between dosing for steady state between  
 
Table 5.  Maximum and minimum concentrations of multiple dosings of ZNS.a 
 
 Max (µg/ml) Min (µg/ml) Fluctuation (%) 
    
Serum 52.45 45.32 13.6 
Plasma 56.01 50.37 10.0 
Whole Blood 55.56 50.43 9.2 
RBC 55.19 50.57 8.4 
    
Mean 54.8 ± 1.6 49.17 ± 2.57 10.3 ± 2.3  
   
  a Data is an average maximum and minimum concentration of the analyzed 
   blood compartments for the 8 dogs after receiving  10.17mg/kg oral for 8 weeks. 
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Fig 4. Multiple dosing concentrations of ZNS. Data collected following 10.17 mg/kg dose for 8 healthy dogs for 8 
weeks followed by 72 hours of elimination data analysis. 
 
Cmax and Cmin was calculated to be 13.6 % (serum), 10 % (plasma),  9.2 % (whole blood), and  
8.4 % (RBC). The AUC(0- ∞) determined from the terminal period of the study in serum (2339.2 ± 
851.28 hr*µg/ml), plasma (2661.6 ± 934.22 hr*µg/ml), whole blood (2990.64 ± 599.76 
hr*µg/ml),  and RBC (3683.04 ± 1008 hr*µg/ml ) were different (p=0.001). Accumulation index 
of ZNSI was , in the respective tissues,  serum (3.26 ± 0.69), plasma (3.52 ± 0.68), whole blood 
(4.30 ± 0.56), and RBC (5.46 ± 1.7). The half-life of ZNS following its discontinuation was 
greater(p= 0.001) in RBC (37.2 ± 12.24 hr) and whole blood (30.9 ± 4.25 hr) compared to serum 
(21.4 ± 5.38 hr) and plasma (23.52 ± 5.76). (Table 6)  
 
Safety 
Clinical pathology 
 Differences in clinical pathology data at the study’s end compared to baselines were 
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Table 6. Pharmacokinetic data of ZNS following multiple dosing oral administration.a 
 
 Serum Plasma Whole Blood RBC p-value 
 (n=8) (n=8) (n=8) (n=8)  
Accumulation Index 3.26A ± 0.69 3.52A ± 0.69 4.30B ± 0.56 5.46C ± 1.7 0.001 
            
AUCINF(observed) 2239.2A ± 851.28 2661.6B ± 934.32 2990.64C ± 599.76 3683.04D ± 1008 0.001 
(hr*ug/mL)           
Lambda_z 0.03A ± 0.01 0.03B ± 0.01 0.02C ± 0.0 0.02D ± 0.01 0.001 
(1/hr)           
t 1/2 21.4A ± 5.38 23.52A ± 5.76 30.96B ±4.32  37.2C ± 12.24 0.001 
(hr)           
 
a Data following administration of oral ZNS (10.17 mg/kg) for 8 weeks, n=8. Parameters are calculated from the 
terminal (elimination) portion after discontinuation of the drug. Letters (A,B,C,D) within each parameter denote 
different compartments (α=0.05, significant when p< 0.05) with Tukey’s HSD. Parameters AUCINF= observed Area 
under the curve measured to infinity, Lambda_z= elimination constant, and t ½= elimination half life. See appendix B 
for equations.  
 
 
reported in several of the tested parameters, although all values were within normal references 
ranges before and at study end. Differences seen in serum alkaline phosphatase (p= 0.0464) and 
serum calcium (p = 0.004)  were greater  than baseline . Serum total protein (p= 0.0071), 
including albumin (p= 0.0266), were both less than the baseline (Table 7).  
 
Thyroid testing 
 Tests indicative of thyroid function differed across time. Total T4 was less at study end 
compared to baseline and decreased to below normal limits by the end of the dosing period. 
Differences in free T4 and TSH from baseline were observed (Table 8). 
   
Urinary testing  
 Urine citrate (p=0.0098) and calcium (p = 0.214) concentrations were greater   at study 
end compared to baseline whereas urinary creatinine concentrations (p = 0.081) and the calcium: 
creatinine ratio (p =0.2873) were both less than baseline (Table 9). 
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           Table 7. Complete blood count and chemistry panel. a 
 
 
 
 
 
 
 
 
 
 
 
 
     a Data reported as a baseline before and after chronic administration of 10.17 mg/kg of ZNS to 8 dogs. 
 Significant if p< α =0.05. Parameters are WBC= white blood cells, RBC= red blood cell, Hgb= hemoglobin, 
 PCV= packed cell volume, MCV= mean corpuscular volume, MCHC= mean corpuscular hemoglobin 
 concentration, BUN= blood urea nitrogen, ALT= alanine aminotransferase,  ALKP= alkaline phosphatase, 
 and  GGT= gamma glutamyltransferase 
 
 
 
                        Table 8. Thyroid hormone concentrations. a 
  Baseline 8 weeks  
Thyroid  Mean Mean P-value 
Free T4 0.07-3.1 ng/dl 1.29± 0.27 1.08±0.35 0.0546 
Total T4 1.61-3.6 ug/dl 1.74±0.57 1.05±0.43 0. 0514 
TSH 0-0.32 ng/dl 0.18±0.2 0.21±0.17 0.1516 
     
 
            a Thyroid hormones were evaluated and compared from beginning of the chronic dose period  
         to the end of the 8 weeks. Student test was used to signify a difference in means. α = 0.05. n=8 
 
 
Parameter reference range Initial Std. dev End Std. dev P-value 
WBC (x 103/ml) 6000-17000 7.21 1.82 10.90 3.72 0.1278 
RBC (x 103/ml) 5.5-8.5 7.25 0.33 6.91 0.13 0.0151 
Hgb (g/dl) 12-18 16.60 0.67 15.93 0.15 0.0131 
PCV (%) 37-55 50.10 1.93 47.46 1.30 0.0172 
MCV (fl.) 60-77 69.19 1.85 68.70 2.47 0.0022 
MCHC (g/dl) 32-36 33.13 0.50 34.40 0.44 0.0120 
Plasma protein (g/dl) 6-8 7.10 0.35 6.83 0.21 0.0122 
Glucose (mg/dl) 60-135 69.86 5.87 81.57 16.26 0.0491 
Cholesterol (mg/dl) 120-247 182.29 47.96 223.29 56.25 0.0641 
BUN (mg/dl) 5.0-29 13.29 5.38 21.00 5.26 0.1409 
Creatinine (mg/dl) 0.3-2 0.96 0.13 1.13 0.18 0.0524 
Magnesium (mg/dl) 1.7-2.1 2.09 0.18 2.11 0.16 0.0042 
Calcium (mg/dl) 9.3-11.8 9.97 0.52 10.11 0.37 0.0045 
Phosphorus (mg/dl) 2.9-6.2 3.74 0.36 4.41 0.72 0.0523 
Total Protein (g/dl) 5.7-7.8 6.49 0.37 6.34 0.40 0.0071 
Albumin (g/dl) 2.4-3.6 3.20 0.14 2.94 0.28 0.0266 
Globulin (g/dl) 1.7-3.8 3.29 0.27 3.40 0.14 0.0109 
ALT (u/L) 10-130 41.71 6.97 34.71 8.75 0.0581 
ALKP (u/L) 24-147 77.00 21.70 89.14 41.56 0.0464 
GGT (u/L) 0-25 12.86 1.95 12.71 2.87 0.0036 
Total Bilirubin 
(mg/dl) 0-0.8 0.12 0.04 0.20 0.00 0.1560 
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            Table 9. Urine citrate, calcium, creatinine, and calcium: creatinine ratio. a 
 
Measurement   Baseline   8 weeks     
Urine Reference Mean Std Dev Mean Std Dev P value 
Calcium mg/dl 1.49 0.45 3.08 3.59 0.214 
Creatinine  mg/dl 259.48 70.58 200.62 37.91 0.081 
Ratio   0.0059 0.0019 0.0171 0.023 0.2873 
Citrate g/ml 44.7 4.32 46.1 7.64 0.0098 
 
                 aThe data was reported in 5 apparently healthy hound dogs receiving zonisamide  
             (10.17 mg/kg twice daily) orally for the 8 week chronic study.  
 
 
Discussion 
 Overall, the effects of multiple dosing indicate that little difference in the kinetics of 
ZNS among the different blood compartments as compared to differences seen following single 
administrations due to RBC. Data collected indicates that equilibrium was reached in all 
compartments by steady state. With sample collection performed once weekly, by day 7 the dogs 
had reached a level that would be consistent with steady state and this corresponds to previous 
estimates of time in chapter III.46 The amount of fluctuation determined from data was 10.3 ± 2.3 
% for serum, plasma, whole blood, and RBC on average. This corresponds to fluctuations of 14 
% following twice daily dosing in humans.8 The amount of fluctuation was used to ensure that 
dosages given maintained the appropriate benefit for therapy. As mentioned in chapter III, the 
accumulation of plasma and whole blood were expected to be 2.02 and 4.09, respectively. Data 
collected supports this estimate with plasma (3.5 ± 0.68) and whole blood (4.3 ± 0.56) being 
similar. With the accumulation of ZNS being great, a reason may be that the dosing interval is 
too short. However, since the elimination half-life is 21.4 to 30.9 hours in plasma and whole 
blood respectively, twice daily dosing is acceptable with the presence of minor fluctuations in 
         34
steady state concentrations. 47  The predicted accumulation index for plasma (2.02) and whole 
blood (4.09) were actually 3.52 for plasma and 4.3 for whole blood. 
 The differences observed in data analysis reveals that the changes in disposition of ZNS 
following single administration differ with interest to the role of RBC. The differences could be 
reflect reversible uptake of ZNS by erythrocytes.11  Once RBC saturation occurred following 
multiple dosing, blood compartments equilibrated and the concentrations and kinetic data 
collected were similar as seen by the figure 4. This equilibration across compartments provides 
evidence that the concentration of ZNS in each of the other compartments can predict total 
systemic concentrations. 
 All dogs tolerated oral ZNS well. Limited reports of diarrhea occurred and were 
determined to be unrelated to the administration of ZNS due to the diarrhea subsiding without 
changes in the dose or dosing interval.  Routine blood work over the course of the chronic study 
was analyzed and all parameters were found to be within normal reference ranges. Variations 
seen in parameters were concluded to be due to daily physiologic changes and could not be 
attributed to affects of ZNS on any one system. 
 Sulfonamide drugs are recognized to negatively impact thyroid function testing in dogs. 
Impairment of thyroglobulin and tyrosine coupling decrease the amount of active thyroid 
hormone produced.27,48 However, total T4, by the end of the study, was lower and indicated 
possible hypothyroidism. Values for free T4 (lower) and TSH (higher), although  within normal 
range, were indicative of possible changes to the  thyroid function.. Increases in TSH are 
attributed to low levels of thyroid hormone negatively inhibiting and slowing the release of 
TSH.48  As circulating levels of thyroid hormones decrease potential problems related 
hypothyroidism: metabolic and gastrointestinal problems can occur.48 
         35
 The carbonic anhydrase inhibitory activity of ZNS may contribute to urolithiasis 
(calcium phosphate or calcium oxalate) by increasing calcium excretion and lowering citrate in 
the urine.11,24 Higher levels of calcium were found in urine samples by study’s end. In response 
to this, the calcium:creatinine ratio was higher which has been previously observed with ZNS 
administration in the development of uroliths.25 Citrate levels were greater by the end, which 
contraindicates the expected result following the administration of a carbonic anhydrase 
inhibitor. Possible reasons could be attributed to problems related to storage or handling of urine 
prior to analysis. Overall, the effects of ZNS on the urinary system seem to be at a minimum, but 
continued evaluation of these parameters would be justified with a urinalysis to determine any 
formation of uroliths. 
 Considering the disposition of ZNS following multiple dosing, determination was made 
that monitoring ZNS concentrations in plasma, serum, and whole blood would provide data 
sufficient to predict the total amount of ZNS within a patient. The amount of fluctuation and 
favorable elimination half-life offers evidence that a dose of 10 mg/kg dosed twice daily would 
ensure that concentrations, considered therapeutic in humans, can be maintained. Evaluation of 
clinical pathology, thyroid testing, and urine analysis would need to be performed to monitor any 
changes which may be to the detriment of the patient.  
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CHAPTER V 
SUMMARY AND CONCLUSION 
Summary 
 Idiopathic epilepsy in the dog is a difficult disease to treat; long-term use of the most 
commonly selected anticonvulsants have associated problems. Data collected through the single 
and multiple dose administration provided evidence that kinetic data collected compare to the 
limited canine research of ZNS disposition.  
 Following single administration, differences observed in the interaction between RBC 
and ZNS were pivotal in explaining the differences that were observed in the disposition of the 
ZNS. The half life was 90.9 hr and 57.4 hr following oral and IV administration, respectively, 
for RBC,  compared to half-lives of 17.2 hr and 12.9 hr following  oral and IV administration, 
respectively, in plasma. The AUC (0-∞) was greater in RBC for both oral and IV data compared to 
the other blood compartments. A MRT of 131.5 hrs in RBC was observed compared to 26.8 hrs 
for both serum and plasma following oral administration. The MRT for IV dosing was greater in 
RBC than the other compartments. The Vd of ZNS following IV administration was 1193.1 
ml/kg for serum, 1096.1 ml/kg for plasma, 673.1 ml/kg for whole blood, and 379.2 ml/kg for 
RBC. Except for RBC, the Vd was indicative of the drug’s ability to move throughout the total 
body water of the dog. Observed parameters for both oral and IV dosing revealed that the RBC 
parameter on a whole was different than the other blood compartments. 
 The changes that were observed due to the effects of RBC following single dosing were 
absent in multiple dosing,  presumably due to the saturation and reversible binding with 
aforementioned RBC.11 A favorable elimination half-life ensures that elimination of the drug 
would not be less than the dosing period which would aide in providing therapeutic benefit to 
patients. The half-life observed ranged from 21.4 hrs to 37.2 hrs for serum and RBC, 
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respectively. The favorable half-life of plasma is important because of plasma’s ability to carry 
free ZNS to brain tissue and interact with tissues to cease induction of seizures. Due to the 
movement of plasma and the interactions with RBC monitoring plasma concentrations would be 
sufficient to predict total ZNS concentrations. Accumulation of ZNS in all blood compartments 
was observed and ranged from 3.2 to 5.4 (Cmax following first dose compared to Cmax at last 
dose). Based on human studies, ZNS concentrations at steady state when receiving 200mg twice 
daily had minor fluctuation (13.5 %) and obtained steady state by day 29.8 The therapeutic level 
suggested for humans in the previous statement was 15-25 µg/ml. In the dog, ZNS had small 
fluctuations (µ= 10.3 %) during the dosing interval following multiple administration. This small 
fluctuation supported the administration of  ZNS twice daily (every 12 hours) as seen in humans. 
Since small differences were observed in multiple dosing and saturation of RBC occurred, 
favorable long-term monitoring of plasma and a recommended dose of 10 mg/kg can be 
implemented..  
 Minor changes in clinical pathology were observed, but all results remained  within 
normal ranges. Despite normalcy throughout this 8 week study period,  metabolism of ZNS, by 
microsomal enzymes of phase I and conjugation of phase II, indicate hepatic function be 
monitored intermittently until sufficient number of animals have been studied to indicate safety. 
 Urinary calcium concentrations and calcium: creatinine urine ratios were greater at study 
end compared to the beginning. This finding may indicate potential formation of urinary calculi, 
and, if unmonitored, this might lead to the formation of uroliths. Monitoring the formation of 
urinary calculi by evaluating the sediment following urinalysis could be performed to monitor 
crystal development. However, the observed urinary citrate concentration was greater by study 
end. This unexpected finding indicates that possibly the movement of citrate in the renal 
structure is impaired and may account for the increased levels of citrate in urine. Changes in the 
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urine (calcium, calcium: creatinine ratio, and citrate) should to be monitored during clinical trials 
to detect the potential for development of uroliths due to the carbonic anhydrase inhibitory 
activity of ZNS. 
 Changes in the thyroid hormone (T4) were observed due to the effects of sulfonamides 26 
and the disruption of the TSH/ thyroid relationship. Thyroid changes were indicative of possible 
hypothyroidism. Total T4 and free T4 were lower at study’s end while TSH was elevated. 
Although the values were insignificant the changes indicate that they need to be monitored in 
long-term therapy to provide evidence based on a larger population to make a determination of 
whether ZNS is goitrogenic.  
 All the data collected was imperative in establishing ZNS disposition and safety 
parameters to consider when implementing and modifying a dosing regimen.  
 
Conclusion 
 In conclusion, a twice daily dose of 10 mg/kg would be sufficient to maintain expected 
therapeutic concentrations. Therapeutic drug monitoring of either serum or plasma would be 
used to accurately predict the concentration of ZNS in systemic circulation. Routine blood work 
and thyroid hormone testing should be performed to note any changes related to administration 
of ZNS. Urolith formation should be monitored by urinalysis looking for urine crystals and 
through the analysis of calcium, calcium: creatinine ratio and microscopic examination for 
crystals (calcium phosphate or calcium oxalate). A pharmacodynamic study would not only help 
with establishing the therapeutic range for control of idiopathic epilepsy, but also provide a 
better representation for potential side effects not evident in this study. 
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APPENDIX A 
Ethanol concentrations 
 
Table 10. Ethanol concentrations related to ethylene glycol treatment dose and LD100. 
 
 
 
 
 
 
 
 
 
The amount of ethanol administered intravenous to each dog over the course of 10 minutes compared to the dogs  
recommended dose for ethylene glycol toxicities which is 20% ethanol infusion 4 times every 6 hours 37 and  the 
lethal  dose of ethanol when administered intravenously.38 
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Figure 1 
 
 
Dog   
                   
Ethanol received   
Ethylene glycol toxicity  
(5 ml/kg) LD100 (5.365g/kg) 
    (ml) (g/kg) (ml) (g) 
1  23.35 0.20 209.55 204.41 
2  19.98 0.20 179.30 174.90 
3  21.08 0.20 189.20 184.56 
4  12.96 0.20 117.70 114.81 
5  16.43 0.20 151.25 147.54 
6  14.76 0.18 150.70 147.00 
7  17.07 0.20 158.40 154.51 
8   15.01 0.20 138.05 134.66 
Fig 5. Ethanol concentration for IV administration. Ethanol concentrations after intravenous 
infusion of ZNS over 360 minutes.  Infusion time was 10 minutes. Standard deviation for each 
concentration plotted. n=8. 
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APPENDIX B 
 Equations  
 
 
WinNonLin® Pharmacokinetic equations 
 
Accumulation index  = [ ])(1 1 τλ −−− ze  
 
   where λz =  first order rate constant related to elimination and τ = dosing 
   interval 
 
AUC: Area under the curve measured with linear trapezoidal method 
 
   =
2
* 212
1
CC
tAUC tt
+= δ  
 
AUCINF: AUC from the time of dosing extrapolated to infinity. 
   =
z
ClastAUClast λ+  
AUMCINF: Area under the moment extrapolated to infinity 
 
   = 2
*
z
Clast
z
ClasttlastAUMClast λλ ++  
 
Clss, Clss/ F: for steady state data is the estimate of total body clearance where F is the fraction 
         absorbed 
   = τ
0AUC
Dose  
    
   = DOSE / AUCINF 
 
 
Lambda z (λz):  First order rate constant associated with the terminal (log-linear) portion of the 
   curve.   
 
t½_Lambda_z: Terminal half-life 
    
   =
zλ
)2ln(  
 
MRTINF: mean residence time (MRT) extrapolated to infinity for non-infusion model 
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   = 
AUCINF
AUMCINF  
 
    for infusion model 
    
   =
2
TI
AUCINF
AUMCINF −  where TI is the length of infusion 
 
 
 
 
Vz, Vz/ F: volume of distribution based on the terminal phase 
   
   
AUCINF
DOSE
z *λ=  
 
 
 
% Fluctuation: Fluctuation for steady state where max and min fall within the dosing interval 
    
   = 100*minmax
Cavg
CC −   
 
Other equations 
 
Protein Binding: = [ ] [ ] 100*
Plasma
BufferPlasma −  
 
 
 
Relative bioavailability (F): 
   F =
( )
OralIV
IVOral
DoseAUC
DoseAUC
*
*
 
 
 
RBC Concentration: = [ ( ) ]PB C1CH
1 H−−  where 
      RBC= Red Blood Cell 
      H= Fractional hematocrit 
      CB = Whole Blood concentration of zonisamide 
      CP= plasma concentration of zonisamide 
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APPENDIX C 
Controls 
 
Table 11. Intra-assay controls for serum, plasma, and whole blood.a 
 
 
 
 
 
 
 
 
 
 
Serum % accuracy= 95.5 ± 4.78 % 
 
 
 
 
 
 
 
 
 
 
Plasma % accuracy= 97.7 ± 6.08 % 
 
 
 
 
 
 
 
 
 
 
Whole blood % accuracy= 92.8 ± 6.06% 
 
a Controls (µg/ml) of selected compartments and the respective % accuracy  with mean and standard deviation for 
each compartment compared against known concentrations of ZNS.  Variability of   ± 15 % was acceptable for 
controls in this study.    
 
 
 
 
 
 
 
 
 
 
 
serum 2 5 7 15 18 20 25 30 60 
          
mean (µg/ml) 2.12 4.64 6.50 13.76 16.98 18.27 23.51 30.09 57.56 
std dev 0.33 0.29 0.91 1.68 1.12 0.48 2.09 1.51 4.79 
precision error 15.57 6.34 14.00 12.21 6.60 2.64 8.91 5.03 8.32 
% Accuracy 106.02 92.88 92.86 91.73 94.36 91.33 94.03 100.31 95.93 
plasma 3 7 15 20 25 45 70 75 90 
          
mean (µg/ml) 2.64 6.79 14.10 19.98 24.15 43.45 68.72 73.29 99.96 
std dev 0.36 0.48 0.95 0.57 2.43 2.87 3.46 10.23 11.07 
precision error 13.61 7.04 6.71 2.84 10.05 6.59 5.03 13.96 11.07 
% Accuracy 87.96 96.98 94.01 99.90 96.58 96.56 98.17 97.72 111.07 
whole blood 1 3 7 15 30 45 70 90 
         
mean (µg/ml) 0.95 2.56 5.88 14.66 29.35 41.33 63.09 90.67 
std dev 0.18 0.25 0.23 0.95 1.69 3.97 1.48 1.40 
precision error 19.31 9.79 3.96 6.47 5.74 9.61 2.35 1.54 
% Accuracy 94.66 85.31 84.06 97.73 97.84 91.85 90.13 100.75 
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          Table 12. Inter-assay controls for  serum, plasma, whole blood, and urine. a 
 
Serum 2 5 7 15 18 20 25 30 60 
          
mean (µg/ml) 1.91 4.89 7.41 14.80 17.75 18.90 24.82 30.93 61.31 
std dev 0.07 0.01 0.00 1.10 0.81 0.42 0.34 0.63 2.17 
precision error 3.90 0.28 0.05 7.46 4.59 2.22 1.37 2.02 3.54 
% Accuracy 95.41 97.75 105.84 98.64 98.63 94.52 99.28 103.10 102.19 
 
Serum % precision = 99.5 ± 3.7 % 
 
Plasma 3 7 15 20 25 45 70 75 90 
          
mean (µg/ml) 3.07 6.75 13.88 19.65 23.05 44.20 71.02 78.05 98.83 
std dev 0.18 0.65 0.20 0.67 0.45 1.37 0.87 8.60 11.70 
precision error 5.70 9.56 1.47 3.41 1.95 3.09 1.22 11.02 11.84 
% Accuracy 102.47 96.47 92.55 98.24 92.19 98.23 101.46 104.06 109.81 
 
Plasma % precision= 99.5 ± 5.6 % 
 
Whole Blood controls 1 3 7 15 30 45 70 90 
         
mean (µg/ml) 0.98 2.62 6.500 15.23 30.32 43.89 64.45 89.51 
std dev 0.03 0.15 0.233 0.29 0.13 3.35 0.17 1.25 
precision error 3.53 5.77 3.964 1.87 0.43 7.64 0.27 1.39 
% Accuracy 98.04 87.48 84.061 101.50 101.08 97.54 92.08 99.45 
 
Whole blood % precision = 95.2 ± 6.5% 
 
 
urine 15 45 70 90 
     
mean (µg/ml) 16.96 42.77 75.79 86.77 
std dev 0.69 2.04 0.60 1.85 
precision error 4.06 4.77 0.79 2.14 
% Accuracy 113.05 95.05 108.27 96.41 
 
Urine %precision= 103.2 ± 8.86% 
 
 
a Controls (µg/ml) of selected compartments and the respective %precision  with mean and standard deviation for each 
compartment compared against known concentrations of ZNS.  Variability of   ± 15 % was acceptable for controls in 
this study. 
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APPENDIX D 
Compartmental Data 
 
Table 13. Compartmental oral pharmacokinetic data of ZNS. a 
  
Serum 
(n=6) 
Plasma 
(n=6) 
Whole Blood 
(n=6) 
RBC 
(n=6) p-value 
AUCINF 358.14A 337.08A 912.53B 2199.70C 0.0000 
(hr*ug/mL) ±89.23 ±85.33 ±213.47 ±501.8   
Vd_F 753.92A 727.44A 525.21B 0.38C 0.0000 
(mL/kg) ± 90.86 ± 136.22 ± 72.47 ± 0.05   
CL_F 30.36A 31.19A 11.47B 0.01B 0.0000 
(mL/hr/kg) ±9.10 ±8.83 ±3.34 ±0   
Cmax 12.56 A 12.58 A 17.81 B 25.27 C 0.0000 
(µg/ml) ± 1.80 ± 1.89 ± 1.41 ± 1.89   
α 2.34 2.18 1.81 2.38 0.8855 
(1/hr) ±1.95 ±1.51 ±1.31 ±2.70   
α half life 0.42 0.44 0.51 0.51 0.7475 
(hr) ±0.19 ±0.28 ±0.24 ±0.29   
β 0.04A 0.04A 0.02B 0.01B 0.0000 
(1/hr) ±0.01 ±0.01 ±0.01 ±0.00   
β half life 18.18A 16.90A 33.12B 58.01C 0.0000 
(hr) ±4.31 ±4.26 ±6.8 ±13.41   
Tmax 2.97 2.89 3.33 3.49 0.7446 
(hr) ±0.91 ±1.06 ±1.13 ±1.58   
MAT 2.34 2.18 1.81 2.38 0.9524 
(hr) ± 3.79 ± 2.27 ± 1.72 ± 7.3  
Tlag 0.73 0.64 0.35 0.12   
(hr) ±0.44 ±0.52 ±0.47 ±0.34   
F 196.85 89.65 98.45 67.52   
 
a Letters (A,B,C) within each parameter denote different compartments (α=0.05, significant when p< 0.05) with 
Tukey’s HSD. Parameters AUCINF= Area under the curve measured to infinity observed, Vd_F= Volume of 
distribution, Cl_F= systemic clearance rate, Cmax= the maximum concentration, α and β are the absorption and 
elimination rate constant, respectively, α and β are the absorption and elimination half lives, respectively,  Tmax= time 
of maximum concentration,  MAT= Mean absorption time, Tlag= Time between administration and absorption, F= 
absolute bioavailability. See appendix B for equations.  
  
 
 Compartmental analysis was performed on the collected ZNS samples to provide 
parameters that noncompartmental analysis could not provide such as absorption and elimination 
rate constants and extrapolated values such as A and B.  After reviewing the data, determination 
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was made not to use the compartmental data because of the small number of acceptable data 
points that were accepted for stripping using the kinetic software. Some of the data collected 
contradicted the definition of the parameter, such as A< B where A, related to absorption, and B, 
related to elimination, should be B>A. Because of the unexplainable results determination was 
made not to use this data.  The collected data for both oral and IV administration are listed below 
to review.  
 
Table 14. Compartmental IV pharmacokinetic data of ZNS. a 
  
Serum 
(n=4) 
Plasma 
(n=5) 
Whole Blood 
(n=4) 
RBC 
(n=5) 
p-value 
 
A 0.84 2.61 2.15 1.24 0.7910 
ug/mL ± 1.08 ± 3.86 ± 1.73 ± 2.24  
α 0.30 0.04 0.02 0.11 0.1067 
(1/hr) ±0.31 ±0.01 ±0.01 ±0.16   
α -HL 9.29A 23.69A,B 41.52B 18.75A,B 0.0136 
(hr) ±9.29 ±13.16 ±10.96 ±13.36   
B 35.11A 38.02A 69.46A 120.9C 0.0000 
ug/mL ± 6.74 ± 5.94 ± 3.71 ± 11.38  
β 0.042A 0.036A,B 0.018B,C 0.006C 0.0004 
(1/hr) ±0.01 ±0.02 ±0.00 ±0.00   
β -HL 16.55A 29.87A 43.31A 88.92B 0.0001 
(hr) ±2.15 ±27.26 ±7.41 ±16.35   
AUCINF 121.58A 251.28A 619.41A 2177.09B 0.0000 
(hr*ug/mL) ±38.38 ±254.68 ±81.39 ±523.47   
CL 8.88A 6.48A 1.63B 0.48B 0.0002 
(mL/hr/kg) ±2.88 ±3.40 ±0.21 ±0.09   
MRT 23.85A 41.95A 62.42A 128.01B 0.0001 
(hr) ±3.10 ±36.83 ±10.61 ±23.27   
Vd 205.37 A 181.70 A 100.45 B 59.46 B 0.0000 
(mL/kg) ± 39.01 ± 30.91 ± 4.97 ± 5.79   
 
a Letters (A,B,C) within each parameter denote different compartments (α=0.05, significant when p< 0.05) with 
Tukey’s HSD. Parameters include A and B = y- intercept for the distribution and elimination phase of the curve, 
respectively; α and β = the absorption and elimination rate constant, respectively; α and β = the absorption and 
elimination half lives, respectively; AUCINF= Area under the curve measured to infinity observed; Cl = systemic 
clearance rate; MRT= mean reside time; and Vd = Volume of distribution. See appendix B for equations.  
 
 
 
 
         50
VITA 
 
Jeremy Dane Perkins 
Permanent Address 
3734 Sunset 
Snyder, TX 79549 
Jeremy_D_Perkins@yahoo.com 
 
Education 
2004 Master of Science in Veterinary Physiology, Texas A&M University 
1999 Bachelor of Science in Biomedical Sciences, Texas A&M University 
 
Professional Experience 
2002-2004 Graduate/Research Assistant to Dr. Dawn Boothe, Department of  
  Veterinary Physiology & Pharmacology, Texas A&M University. 
2001-2002 Oncology Technician, North Texas Veterinary Referral Clinic, Animal  
  Diagnostic Clinic, Dallas, TX. 
2000-2001 Surgical Technician, Texas A&M Small Animal Clinic. 
 
 
 
 
